Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > Upfront Fee Material Information?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(30)
•••
Comment by jimmyhorizonon Jul 07, 2022 10:20am
141 Views
Post# 34808132

RE:RE:RE:RE:RE:RE:Upfront Fee Material Information?

RE:RE:RE:RE:RE:RE:Upfront Fee Material Information?

biorun wrote: yes, they are required to report all money coming into the coffers as you indicate, but abbvie also has to report a 10k in august where they "may" also be required to disclose certain details. we will see what that brings. 

if that does surface and it is in fact more than lcfsa insists, then expect an immediate revaluation within the hour. right now we are trading with near full doubt the economic impact of the deal with abbvie is negligible, thanks to the bashers here.

 

thank you. 

To be clear. If they had received, let's say, 10m upfront in their account last week, then they would only have to disclose this in the next quarterly figures?
is that correct?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities